✦ LIBER ✦

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

✍ Scribed by Carlos H. Barrios; David Hernandez-Barajas; Michael P. Brown; Se-Hoon Lee; Luis Fein; Jin-Hwang Liu; Subramanian Hariharan; Bridget A. Martell; Jinyu Yuan; Akintunde Bello; Zhixiao Wang; Rajiv Mundayat; Sun-Young Rha

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 855 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26440

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 dose-escalation trial of tremeli

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

✍ Brian I. Rini; Mark Stein; Pat Shannon; Simantini Eddy; Allison Tyler; Joe J. St 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 273 KB 👁 2 views

Phase II study of paclitaxel and epirubi

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

✍ Giovanni L. Ceresoli; Stefania Dell'Oro; Paolo Passoni; Eugenio Villa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

Phase II trial of 5-fluorouracil, interf

Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

Randomized multicenter Phase II trial of

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

✍ Emilio Bajetta; Maria Di Bartolomeo; Luigi Mariani; Antonio Cassata; Salvatore A 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract ## BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first‐line treatment in metastatic colorectal carcinoma (CRC). ## METHODS A total of 140 patients received capecitabine at a dose of 1

A high rate of venous thromboembolism in

A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

✍ Apurva A. Desai; Nicholas J. Vogelzang; Brian I. Rini; Rafat Ansari; Stuart Krau 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5‐FU) and daily oral thalidomide in patients with metastatic renal cell carcinoma (RCC). ## METHODS B